Comparison of Three Autogenous Bone and Xenograft Ratios for Horizontal Ridge Augmentation

NCT07869485 | Not Yet Recruiting

• 1 other identifier: PER 6-3-3
• Study Type: interventional
• Target: 45
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study will compare three different ratios of autogenous bone and xenograft used for horizontal alveolar ridge augmentation in patients with insufficient bone width for dental implant placement. Participants will be randomly assigned to receive one of three bone graft mixtures: 50% autogenous bone and 50% xenograft, 75% autogenous bone and 25% xenograft, or 25% autogenous bone and 75% xenograft. The aim of the study is to determine whether the different bone graft ratios result in different amounts of horizontal bone gain. Bone changes will be assessed clinically and using cone-beam computed tomography (CBCT) during follow-up.

Conditions

Horizontal Alveolar Ridge Deficiency

Keywords

Guided Bone Regeneration Horizontal Ridge Augmentation Alveolar Ridge Augmentation Autogenous Bone Xenograft Bone Graft Sausage Technique

Outcome Measures

Primary Outcomes (1)

• Radiographic Horizontal Bone Gain

  The change in horizontal alveolar ridge width from baseline to 6 months after horizontal ridge augmentation, measured radiographically using cone-beam computed tomography (CBCT).

  Baseline to 6 months after augmentation

Secondary Outcomes (10)

• Clinical Horizontal Bone Gain

  6 months after augmentation

• Vertical Bone Gain

  Baseline to 6 months after augmentation

• Histomorphometric Bone Quality

  6 months after augmentation

• Soft Tissue Thickness

  Baseline and 3 and 6 months after augmentation

• Keratinized Tissue Width

  Baseline and 3 and 6 months after augmentation

Study Arms (3)

50:50 Autogenous Bone-Xenograft

EXPERIMENTAL

Participants will receive horizontal alveolar ridge augmentation using a 50:50 mixture of autogenous bone and xenograft, covered with a collagen membrane using the sausage technique.

Procedure: 50:50 Autogenous Bone-Xenograft

75:25 Autogenous Bone-Xenograft

EXPERIMENTAL

Participants will receive horizontal alveolar ridge augmentation using a 75:25 mixture of autogenous bone and xenograft, covered with a collagen membrane using the sausage technique.

Procedure: 75:25 Autogenous Bone-Xenograft

25:75 Autogenous Bone-Xenograft

EXPERIMENTAL

Participants will receive horizontal alveolar ridge augmentation using a 25:75 mixture of autogenous bone and xenograft, covered with a collagen membrane using the sausage technique.

Procedure: 25:75 Autogenous Bone-Xenograft

Interventions

50:50 Autogenous Bone-Xenograft PROCEDURE

Horizontal alveolar ridge augmentation using a 50:50 mixture of autogenous bone and xenograft with a collagen membrane using the sausage technique.

50:50 Autogenous Bone-Xenograft

75:25 Autogenous Bone-Xenograft PROCEDURE

Horizontal alveolar ridge augmentation using a 75:25 mixture of autogenous bone and xenograft with a collagen membrane using the sausage technique.

75:25 Autogenous Bone-Xenograft

25:75 Autogenous Bone-Xenograft PROCEDURE

Horizontal alveolar ridge augmentation using a 25:75 mixture of autogenous bone and xenograft with a collagen membrane using the sausage technique.

25:75 Autogenous Bone-Xenograft

Eligibility Criteria

• Age: 20 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age from 20 to 70 years.
• Patients with multiple missing mandibular posterior teeth (2 or more).
• Patients with compromised bone width in the posterior mandible (≤4 mm) and adequate bone height (not less than 9 mm).
• Patients with healthy systemic condition.
• Adequate inter-arch space for placement of the implant prosthetic part (8-12 mm).
• Good oral hygiene.
• Cooperative patients who are willing to commit to 6 months of follow-up.

You may not qualify if:

• Smokers.
• Pathological lesions (abscess, cyst, or acute infection) at the defect site.
• Pregnant females.
• Uncontrolled diabetic patients.
• Patients taking medications or receiving treatments that may interfere with healing, including corticosteroids, bisphosphonates, chemotherapy, or radiotherapy.

Sponsors & Collaborators

• Eslam hisham mohamed: lead
• Geistlich Pharma AG: collaborator

Study Officials

• eslam hisham mohamed, B.Sc.

  Department of Oral Medicine and Periodontology, Faculty of Dentistry, Cairo University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

eslam hisham mohamed, B.Sc.

CONTACT

+201117182392; eslam.younes@dentistry.cu.edu.eg

Hani elnahass, Prof.Dr.

CONTACT

+20 10 00252603; hani.elnahass@dentistry.cu.edu.eg

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Masking Details: The outcome assessor will be blinded to the treatment group allocation during outcome assessment.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Master's student

Study Record Dates

• First Submitted: October 6, 2026
• First Posted: October 9, 2026
• Study Start: October 1, 2026
• Primary Completion (Estimated): September 1, 2027
• Study Completion (Estimated): September 1, 2027
• Last Updated: October 9, 2026

Record last verified: 2026-10

Data Sharing

• IPD Sharing: Will not share